Maureen Hewitt, MD
Hematology & Oncology · West Chester, PANPI 1447312368
Payments from drug & device makers
What this record shows
This record is dominated by education: $188 of the $257 with a category attached, or 72.9%. Servier Pharmaceuticals LLC accounts for 61.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $171 and has fallen 81.9% since, to $31 in 2025. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 10 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$159
- Siemens Medical Solutions USA, Inc.$31
- Pharmacyclics LLC, An Abbvie Company$21
- Hologic Sales And Service, LLC$17
- Merck$16
- Gilead$12
- plus $1 from 1 others
Across 2 payments — averaging $15,566 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$31K
What the payments were for
- Food & beverage$7027%
- Education$18873%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 4 | $159 |
| Siemens Medical Solutions USA, Inc. | 1 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Merck | 1 | $16 |
| Gilead | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $1 |
How this compares
$257 in reported general payments places this provider in the 20th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 23 | $395,994 |
| IbrancePalbociclib | 20 | $317,449 |
| LynparzaOlaparib | 14 | $218,697 |
| KisqaliRibociclib Succinate | 11 | $172,050 |
| RevlimidLenalidomide | 12 | $132,947 |
| EliquisApixaban | 94 | $74,700 |
| XareltoRivaroxaban | 48 | $50,439 |
| Anastrozole | 189 | $4,696 |
| Exemestane | 16 | $2,647 |
| Tamoxifen Citrate | 51 | $1,357 |
| Hydroxyurea | 34 | $1,016 |
| Letrozole | 58 | $917 |
| Gabapentin | 47 | $512 |
| Alendronate Sodium | 40 | $446 |
| Ibandronate Sodium | 13 | $425 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in West Chester
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.